VNS Therapy™ can lead to fewer seizures, shorter seizures and better recovery after seizures.
AspireSR™- Advancing the treatment of drug-resistant epilepsy with responsive VNS Therapy™
- Proven efficacy and safety of VNS Therapy1
- Helps stop or shorten a seizure by responding to a rapid increase in heart rate, that may be associated with seizures2
- Helps prevent seizures by delivering treatment at regular intervals all day, every day2
- May reduce seizure duration and seizure severity and improve post-ictal recovery3
- Improves quality of life3
VNS Therapy™ works to control seizures in three ways
Helps to reduce seizures
Stimulation is delivered at regular intervals all day, every day, to help reduce seizures16
Responds to rapid increases in heart rate*
An extra dose of therapy is automatically delivered at the sign of a rapid increase in heart rate, which may be associated with seizures16
*Only available in Models 106 and 1000
Delivers On-Demand Treatment
Stimulation is manually delivered by swiping the VNS Therapy™ magnet over the generator to help stop or shorten a seizure once it starts16
AspireSR™ detects and responds to rapid increases in heart rate, that may be associated with a seizure2
Over 60% of treated seizures ended during automatic stimulation†
The closer the stimulation to seizure onset, the shorter the seizure duration4
The change from regular to responsive VNS TherapyTM showed a reduction of seizure frequency
Based on the McHugh Classification of patients receiving VNS Therapy:
12 out of 19 patients (41%) who had less than 50% seizure reduction with regular VNS Therapy reported more than 50% seizure reduction with responsive VNS Therapy following a battery change.
This study was a non-controlled retrospective analysis of data where the seizure reporting is an interpretation of patients and carers.
*Conventional VNS Therapy in this article refers to models before AspireSR without the cardiac based seizure detection and closed loop stimulation. **Responsive VNS Therapy in this article refers to AspireSR model.
VNS Therapy™ has no drug interactions and does not cause drug-related toxic central nervous system side effects.
Common side effects include hoarseness or change in voice tone, shortness of breath, sore throat, and coughing. Most side effects associated with VNS Therapy occur only during stimulation, tend to diminish over time, or are eliminated by adjusting parameter settings.
The most common side effect of the surgical procedure is infection. Children under 12 may have a greater risk of infection than those 12 years of age and older and may be more likely to experience lead damage due to higher activity levels and the potential to manipulate the lead.
For more safety information click here.
*Responsive VNS Therapy™ refers to VNS Therapy devices with AutoStim Mode enabled. Available in models 106 and 1000, 1000-D
†Individual study example (N=28/46). Results may vary.
1. Elliott R.E. et al. Epilepsy & Behavior, 20 (2011) 57–63 2. VNS Therapy System™ Epilepsy Physician’s Manual, January 2021, LivaNova, Houston, TX. 3. Orosz I. et al. Epilepsia, 55(10):1576–1584, 2014 4. Data on file, LivaNova, Inc., Houston, TX. 5. Hamilton, P., et al. (2018) Seizure 58:120-126. 16. VNS Therapy™ System Epilepsy Physician’s Manual April 2021, 76-0000-5600/8 (OUS)
This website is intended for healthcare professionals in Australia. VNS Therapy™ for drug-resistant epilepsy is not available in all regions - please refer to your country-specific labeling.